- Open Access
Pleurodesis with pseudomonas aeruginosa-mannose–sensitive hemagglutinin for pneumothorax secondary to COPD: a retrospective study
© The Author(s). 2017
- Received: 3 April 2016
- Accepted: 2 January 2017
- Published: 10 January 2017
Pneumothorax is a potentially life-threatening complication of chronic obstructive pulmonary disease (COPD) that leads to cardiopulmonary compromise. According to the British Thoracic Society (BTS) guidelines, medical pleurodesis is recommended for inoperable patients suffering from COPD-related pneumothorax. Several sclerosing agents are currently in use, but none have been proven to be the best choice, as each one has effectiveness and safety issues. Recent research has shown that Pseudomonas aeruginosa-mannose–sensitive hemagglutinin (PAMSHA) is a safe bioagent with low toxicity and good immune-boosting effects that can induce the aseptic inflammation necessary to cause pleural adhesion.
The aim of this study is to report our experience using PAMSHA in medical pleurodesis to treat inoperable cases of persistent pneumothorax secondary to COPD.
Records of 78 inoperable patients with persistent pneumothorax secondary to COPD treated with PAMSHA pleurodesis were retrospectively reviewed. Pleurodesis was performed by administering 1 ml of PAMSHA (mixed with lidocaine and 30-40 ml of normal saline) intrapleurally.
The resolution of pneumothorax was observed in all of the patients treated with PAMSHA pleurodesis (success rate = 100%). Some of them experienced mild chest pain and fever, but no long-term side effects were reported.
Our data suggest that PAMSHA pleurodesis is a safe and effective option for the treatment of persistent pneumothorax secondary to COPD.
- Intrapleral injection
- Chronic obstructive pulmonary disease
- Secondary spontaneous pneumothorax
Secondary spontaneous pneumothorax (SSP) occurs as a complication of certain lung diseases, the most common of which is chronic obstructive pulmonary disease (COPD). Approximately 50-70% of SSP cases are attributed to COPD [1–4], and SSP in COPD occurs when subpleural bullae form and eventually rupture. This leads to persistent air leakage into the chest and worsens the symptoms of dyspnea already caused by COPD. According to the British Thoracic Society (BTS) guidelines, the management of SSP includes oxygen supplementation, the insertion of a chest drain, and active intervention by thoracic surgery. However, among patients with SSP who are unfit for surgery, medical pleurodesis is offered as an appropriate alternative . Despite the attractiveness of this non-surgical approach, its indication and the selection of the sclerosing agents used for the procedure are still debated, and the results are poorly defined.
To help shed more light on this matter, we present our study of the use of Pseudomonas aeruginosa-mannose–sensitive hemagglutinin (PAMSHA) for the pleurodesis of patients with pneumothorax secondary to COPD. We hope that this report will add knowledge of the ways in which SSP is treated.
Study design and ethics board approval
Records of patients who underwent PAMSHA pleurodesis at our hospital’s surgical ward from January 2011 to December 2013 were retrieved for the purpose of reviewing the effects of this intervention. The interventions were performed due to an increasing number of recurrent COPD-related pneumothorax cases in the surgery ward of our hospital. After a discussion with colleagues, our surgical team decided to investigate the efficacy and safety of the agent PAMSHA for pleurodesis of these affected patients. With the approval of the department chair and the ethics board/committee of the hospital (The First Affiliated Hospital of Shantou University Medical College Ethics Review Form – Science Research -No. 2015075), we invited patients who had suffered from COPD-related pneumothorax with persistent air leaks for two weeks to enroll in our intervention. According to the enrollment criteria, these patients must have already received treatment for two weeks consisting of the following: thoracostomy tube placement at the time of admission, guideline-recommended antibiotics for their specific conditions, patient-specific cardiopulmonary and nutritional support, and oxygen supplementation. After discussion of the risks and benefits of the procedure, those who enrolled were asked to sign an informed consent form.
The PAMSHA used was from the Beijing Wanter Biopharmaceutical Company Ltd (Beijing, China). It was in liquid form and packaged as 1.0 ml of solution per ampule. For our intervention, we added 1.0 ml of PAMSHA to a mixture of 50 ml of lidocaine (5 ml/0.1 g) and 30-40 ml of 0.9% NaCl saline solution. All of the mixture was used in each administration.
Procedure of administration and monitoring
Skin testing for hypersensitivity was performed prior to intrapleural administration of the agent. After skin testing, the sclerosing agent was prepared for administration (aseptic procedures included). With the patient in the supine position, the tube was clamped 10 cm away from the chest wall. The sclerosing agent was then injected 5-6 cm proximal to the clamped end, and the puncture site was sealed with adhesive plaster. To evenly distribute the sclerosing agent, each patient was asked to change position in various ways - from left decubitus to right decubitus, from supine to prone position, and with the head and upper chest elevated. The patient assumed each position for 15 min, and the thoracostomy tube was monitored throughout all position changes. As it was possible to aggravate the pneumothorax throughout the procedures due to insufficient drainage of air, all patients were observed and monitored for cardiorespiratory problems. The tube was unclamped and reclamped every 6-8 h post-injection to monitor for air leakage. For patients who did not report severe adverse effects like chest pain and fever after the first injection, repeated injections of 2 ml of PAMSHA (mixed with 30-40 ml of 0.9% NaCl and 5 ml of lidocaine) were administered on alternate days (3rd, 5th, etc.) until signs of air leakage were no longer observed in the water-sealed container. If severe adverse effects occurred, a standby supportive therapy plan was put in place, and the repetition of the injections was postponed to 4 to 5 days after. The patients were monitored for improvement through clinical assessments (interviews, self-reports, and physical exams) and imaging studies (chest x-rays), and it was expected that air leakage would not be observed after 3 injections.
Results of the selected diagnostic tests
Frequency [Percentage (n)]
Hypercarbia (PaCO2 > 45 mmHg) and hypoxemia (PaO2 < 55 mmHg) based on arterial blood gas analysis
VC < 1 L (<50% of the predicted value), FEV1 < 0.5 L (<40% of the predicted value), MVV < 50% of the predicted value, FEV1/VC <0.7 in pulmonary function tests
Confirmed pneumothorax with diffuse emphysema and subpleural bullae from CT or chest X-ray
Breath-holding test < 15 s
All of the patients had undergone thoracostomy tube placement at the time of their admission, and they had also been provided with other supportive measures such as oxygen supplementation, cardiopulmonary stabilization, and infection control using guideline-recommended antibiotics.
Incidence of main short-term side effects
Complications / Intervention
Patients (78) [Percentage (n)]
Fever only (<38.5 °C) / observation
Mild chest paint only / given oral indomethacin
Fever (>38.5 °C) and chest pain / oxygen uptake, oral indomethacin
Severe chest pain and dyspnea / oxygen uptake, intravenous steroid injections, and oral indomethacin
COPD is a severe lung disease characterized by persistent airflow limitation that progresses over time. In China, it has a prevalence rate of 8.2% in those over 40 years of age. Diffuse emphysema and subpleural bullae are often found on chest x-rays, and these bullae are the main causes of persistent air leakage, which is difficult to treat. Once air leakage occurs, it devastates the patients because their baseline lung function becomes more limited, and it pushes them to undergo a surgical procedure under general anesthesia . The post-operative complications could also jeopardize their general condition, so the management of pneumothorax secondary to COPD is complicated. Furthermore, patients with this condition could suffer from pneumonia and respiratory failure after lung volume reduction surgery, making it difficult for them to be weaned from ventilators.
The main objective of management of patients with COPD complicated by pneumothorax is to stop air leaks using relatively simple and safe methods, and various methods have been used to meet this objective. If a patient is still in good condition and an operation is tolerable, surgical removal of the subpleural bullae is considered the first line treatment. This prevents the enlarging bullae from gradually compressing the normal lung tissues. However, surgical intervention appears to be a radical method for recurrent pneumothorax, and there are patients who cannot undergo such a procedure. The management of COPD-related pneumothorax by bronchial occlusion in combination with talc powder has been reported to be successful in three cases . Though no recurrences were observed for more than 1 year, the long hospitalization and complex procedure associated with it made it less favorable. Tube thoracostomy is effective in providing symptomatic improvement, but when it is repeated, it can be a physical and emotional burden to the patients. Another method is to rub the pleural membranes during surgical intervention, which leads to pleural adhesion and prevents the recurrence of pneumothorax. According to the BTS guidelines, medical pleurodesis remains the first choice for treating persistent air leakage , as it is safe and easy to perform. It induces pleural adhesion through aseptic inflammation and is indicated for patients with near-normal pulmonary function and no obvious bullae on CT imaging. However, the use of this method has problems, as there is no consensus yet on the best technique to follow. Additionally, the sclerosing agents used for this procedure have variable efficacy and safety.
A recent meta-analysis confirmed the superiority of talc as a sclerosing agent. Talc use can induce intense intrapleural inflammation by producing numerous pro-fibrotic factors that cause adhesions and fibrosis between the pleural membranes . Common side effects of talc include fever (10-17%), pain, and gastrointestinal symptoms. Less common side effects include arrhythmia, dyspnea, respiratory failure, a systemic inflammatory response, empyema, and the dissemination of talc to other regions [8–10]. However, talc particles and other pro-fibrotic factors hypothetically have the potential to be absorbed and lead to systemic inflammation. This problem has raised questions about the safety of talc as a sclerosing agent . Therefore, scientists are still searching for the most suitable sclerosing agent for pleurodesis – one that could yield a high success rate with a low risk of severe adverse reactions.
Mannose-binding hemagglutinins in extracts of Pseudomonas aeruginosa were first proposed in 1977 and have now gained more consideration because of their anti-tumor effects . Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PAMSHA) is a peritrichous P. aeruginosa strain with MSHA fimbriae that can inhibit activation of the epidermal growth factor receptor signaling pathway in tumor cells . Animal studies have shown that PAMSHA affects both the pro-inflammatory and anti-inflammatory processes, which help limit the severe adverse reactions caused by systemic inflammation . In other studies, it has been reported to induce apoptosis in tumor cells and improve immune function, which can prevent metastasis and the recurrence of certain types of cancer [14–19]. It has also been used to treat malignant pleural effusion [20–22].
In this study, we report our experience performing pleurodesis using PAMSHA as the sclerosing agent. We think that this method is more convenient than bronchial occlusion followed by the addition of talc powder. Medical pleurodesis with PAMSHA can produce similar results but without the risk of severe side effects and the trouble of doing a multi-step procedure. After observing the effects of the intrapleural administration of PAMSHA in 78 inoperable cases of pneumothorax secondary to COPD, our follow-up imaging studies showed signs of resolution of the pneumothorax. After a year of follow-up, none of our patients reported readmission due to recurrence of a pneumothorax. For us, this is enough information to report that we had a success rate of 100% for the procedure. Additionally, adverse effects such as chest pain and low-grade fever were only transient and resolved well with supportive care. No gastrointestinal and neurologic dysfunction, bone marrow inhibition, or liver/kidney impairment were reported.
There are limitations to this study. First, this study was retrospective, and there was no standardized evaluation of the inoperability of the patients from the perspective of pulmonary function. Second, the reporting of adverse effects after pleurodesis was relatively subjective and did not employ standardized scoring systems to quantify clinical improvement properly. We believe that a prospective study with precise definitions of the variables and a standardized treatment protocol will be helpful in validating our results.
Pleurodesis is an appropriate treatment for pneumothorax secondary to COPD. However, choosing a highly effective and safe sclerosing agent for this procedure is still controversial. Clinician preferences, agent characteristics (efficacy and safety), and commercial availability are factors that contribute to the selection of a sclerosing agent.
Given the success rate and minimal amount of minor complications reported, we conclude that PAMSHA is an effective and safe sclerosing agent that can be used to treat patients who have pneumothorax secondary to COPD. However, further studies are needed to confirm our conclusion.
The authors would like to thank the Surgery Department of the First Affiliated Hospital of Shantou University Medical College for their support of this project. This work was supported by the Science and Technology Planning Project (No. 2015-37) of the Shantou Municipal Science and Technology Bureau.
HW was the primary investigator of the study. He did all the treatment procedures at the wards, conceptualized the study, reviewed and collected data from the medical records, analyzed the results, and wrote the abstract, background, results and conclusion parts of the manuscript. DL assisted HW in conducting the treatment procedures, did the literature review, and wrote the discussion and reference list of the manuscript. PYT wrote the method part of the manuscript, helped analyzed the results, and revised the manuscript for third party editing and subsequent submission. WW and SZ assisted HW at the wards, reviewed some of the medical records, and collected data for Table 2. All authors read and approved the final manuscript.
The authors declared that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Decker D, Tolba R, Springer W, et al. Abdominal surgical interventions:local and systemic consequences for the immune systemaprospective study on elective gastrointestinal surgery [J]. J Surg Res. 2005;126(1):12–8.View ArticlePubMedGoogle Scholar
- Noppen M, De Keukeleire T. Peumothorax. Respiration. 2008;76:121.View ArticlePubMedGoogle Scholar
- Chen CH, Liao WC, Liu YH, et al. Secondary spontaneous pneumothorax: which associated conditions benefit from pigtail catheter treatment? Am J Emerg Med. 2012;30:45.View ArticlePubMedGoogle Scholar
- Guo Y, Xie C, Rodriguez RM, Light RW. Factors related to recurrence of spontaneous pneumothorax. Respirology. 2005;10:378.View ArticlePubMedGoogle Scholar
- Henry M, Arnold T, Harvey J. Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of spontaneous pneumothorax. Thorax. 2003;58 suppl 2:ii39–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Ishida A, Kida H, Muraoka H, Nishine H, Mineshita M, Miyazawa T. Intractable pneumothorax managed by talc pleurodesis and bronchial occlusion with spigots. Respiry Case Rep. 2015;3(1):13–5.Google Scholar
- Genofre EH, Marchi E, Vargas FS. Inflammation and clinical repercussions of pleurodesis induced by intrapleural talc administration. Clinics (Sao Paulo). 2007;62:627.View ArticleGoogle Scholar
- Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. 2004;(1):CD002916.Google Scholar
- Laisaar T, Palmiste V, Vooder T, Umbleja T. Life expectancy of patients with malignant pleural effusion treated with video-assisted thoracoscopic talc pleurodesis. Interact Cardiovasc Thorac Surg. 2006;5:307.View ArticlePubMedGoogle Scholar
- Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest. 1996;110:1387.View ArticlePubMedGoogle Scholar
- Gilboa-Garber N, Mizrahi L, Garber N. Mannose-binding hemagglutinins in extracts of Pseudomonas aeruginosa. J Biochem. 1977;55(9):975–81.Google Scholar
- Chang L, Xiao W, Yang Y, et al. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits epidermal growth factor receptor signaling pathway activation and induces apoptosis in bladder cancer cells in vitro and in vivo[J]. Urol Oncol. 2014;32(1):e11–18.View ArticleGoogle Scholar
- Zhu H, Wang S, Shen L, Wang W, et al. Effects of Pseudomonas aeruginosa mannose-sensitive hemagglutinin (PAMSHA) pretreatment on septic rats. Int Immunopharmacol. 2013;17(3):836–42.View ArticlePubMedGoogle Scholar
- Cao Z, Shi L, Li Y, Wang J, Wang D, Wang G, Sun B, Mu L, Yang M, Li H. Pseudomonas aeruginosa: mannose sensitive hemagglutinin inhibits the growth of human hepatocarcinoma cells via mannose-mediated apoptosis. Dig Dis Sci. 2009;54(10):2118–27.View ArticlePubMedGoogle Scholar
- Li T, Dong ZR, Guo ZY, Wang CH, Zhi XT, Zhou JW, Li DK, Chen ZT, Chen ZQ, Hu SY. Mannose-mediated inhibitory effects of PAMSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/Ikt/NF-kB pathway. Liver Int. 2015;35(4):1416–29.View ArticlePubMedGoogle Scholar
- Liu ZB, Hou YF, Di GH, Wu J, Shen ZZ, Shao ZM. PAMSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines. J Cell Biochem. 2009;108(1):195–206.View ArticlePubMedGoogle Scholar
- Zhang ZM, Dai HB, Zhou Q. Effects on Lymphocytes apoptosis and immune funtion after stimulating K562 cell lines with Pseudomonas aeruginosa-mannose-sensitive hemagglutinin [J]. China J Pharmacol. 2007;42(16):12224–7.Google Scholar
- Ling W, Liu H, Cao H, et al. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin prevents recurrence and metastasis post-gastectomy [J]. China Pract J Surg. 2009;11(29):933–6.Google Scholar
- Hao W, Yi L, Li-li T. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin for cancerous ulceration of breast cancer. ZhongNan Pharm. 2010;8(1):64–6.Google Scholar
- Mateen HU, Francisco AA, Mona GS, et al. Management of malignant pleural effusions [J]. Adv Ther. 2010;27(6):334–47.View ArticleGoogle Scholar
- Li WAN, Geng-jing HE. Clinical observation for Pseudomonas aeruginosa-mannose-sensitive hemagglutinin use in malignant pleural effusion. Clin Lung J. 2013;18(3):401–2.Google Scholar
- Feixue S, Xiaxia P, Qimei J, Yan P, ZHAO J, Ji XIE. Effects for Pseudomonas aeruginosa-mannose-sensitive hemagglutinin use in malignant pleural effusion [J]. China Clin Tumor. 2013;40(18):1127–9.Google Scholar